Phibro Animal Health Signals Strong Momentum in Earnings
Phibro Animal Health Corp ((PAHC)) has held its Q2 earnings call. Read on for the main highlights of the call.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Phibro Animal Health Corp struck a notably upbeat tone on its latest earnings call, underscoring strong momentum in its core Animal Health franchise and the successful integration of its acquired MFA portfolio. Management acknowledged some near‑term headwinds in legacy MFA, Performance Products and cash flow, but framed these as transitory against broad‑based revenue growth, margin expansion and higher full‑year guidance.
Surging Consolidated Sales Underpin Earnings Momentum
Consolidated net sales for the quarter ended Dec. 31, 2025 climbed to $373.9 million, a 21% year‑over‑year increase driven by stronger demand and a favorable mix. The robust top‑line performance provided the foundation for improved profitability, even as certain smaller segments and timing issues introduced some volatility beneath the surface.
Animal Health Segment Leads With Outsized Growth
Animal Health remained the growth engine, with net sales jumping 26% to $290 million and adjusted EBITDA surging 41% to $82.2 million. A full quarter of contribution from the newly acquired MFA assets delivered $94.1 million in sales, helping push MFA and related growth to roughly 34% and underscoring the strategic importance of this portfolio.
Adjusted Profitability Expands on Mix and Leverage
Adjusted EBITDA rose by $19.9 million, or 41% year over year, reflecting both volume gains and richer product mix. Adjusted net income increased 60% and adjusted diluted EPS advanced 58%, highlighting meaningful operating leverage as higher‑margin Animal Health offerings scaled across the portfolio.
Free Cash Flow Positive Despite Working Capital Drag
Over the twelve months ended Dec. 31, Phibro generated $93 million of operating cash flow and $47 million of free cash flow after $46 million of capital expenditures. The company also returned cash to shareholders via a quarterly dividend of $0.12 per share, totaling $4.9 million, signaling confidence in its cash generation capacity despite some near‑term working capital investment.
MFA Integration and Commercial Execution Gain Traction
Management highlighted strong operational execution in integrating the MFA portfolio, citing positive customer feedback at industry events and visible commercial momentum. The company reported share gains in categories such as broiler coccidiosis and swine enteritis, supported by improved coordination across regional teams following leadership meetings and global alignment efforts.
Diverse Product and Regional Growth Drivers Emerge
Beyond MFA, Phibro saw 9% growth in nutritional specialties, adding $4.3 million on the back of healthy North American dairy demand. Vaccine revenue climbed 13%, or $4.5 million, driven mainly by poultry in Latin America and higher international orders, while the newly launched companion‑animal product Restore showed encouraging early uptake.
Legacy MFA Faces Temporary Volume Pullback
Not all MFA trends were positive, as legacy MFA sales slipped 5% due to the timing of inventory purchases by a key customer, shaving about $10 million from the quarter. Management emphasized that this was a timing issue rather than a demand problem and expects volumes to rebound in the second half, although investors should anticipate some ongoing lumpiness.
Performance Products Segment Remains a Weak Spot
The smaller Performance Products segment continued to struggle, with net sales down 10% to $15 million amid softer demand for ingredients used in personal care products. Adjusted EBITDA for this business was just $0.8 million, underscoring margin pressure and highlighting that this portfolio currently contributes little to overall profit growth.
Inventory Build Weighs on Working Capital and Cash
Phibro disclosed that it has built inventory to advance‑stock against tariffs and to prepare for rising customer demand, a strategy that temporarily pressured working capital and muted cash conversion. Management expects inventory levels to normalize over coming quarters, which should support improved cash flow metrics if sales momentum persists.
Higher SG&A and Interest Costs Temper Upside
Adjusted SG&A expenses increased, with corporate costs up $3.7 million largely due to higher employee‑related spending needed to support growth and integration. Rising interest expense also partially offset gross profit gains, limiting the portion of incremental revenue that flowed through to adjusted EBITDA and underscoring the cost of the company’s capital structure.
Leverage Profile Manageable but Elevated
Total debt stood at $737 million, equating to gross leverage of about 3.1 times and net leverage of roughly 2.8 times trailing twelve‑month adjusted EBITDA of $235 million. While management portrayed these levels as manageable, the company’s leverage remains a key metric for investors to monitor, particularly as integration initiatives and growth investments continue.
Guidance Raised on Strength in Animal Health and MFA
Phibro raised its fiscal 2026 outlook, now targeting net sales of $1.45 billion to $1.50 billion, implying 12% to 16% growth at the top line with a midpoint near 14%. Adjusted EBITDA guidance moved up to $245 million to $255 million and adjusted net income to $120 million to $127 million, signaling management’s confidence that strong Animal Health performance, MFA contribution and Phibro Forward initiatives will translate into outsized profit growth.
Phibro’s latest earnings call painted a picture of a company leaning into its Animal Health strengths while managing through a handful of manageable, near‑term headwinds. With revenue and margins expanding, guidance moving higher and integration tracking well, the story now hinges on execution in cash generation and leverage reduction, areas investors will watch closely in coming quarters.
